Antimalarials and cholesterol profile of patients with systemic lupus erythematosus

Revista Brasileira de Reumatologia

Volumn 51, Issue 4, 2011, Pages 383-387

  Rossoni, Carina ^a   Bisi, Melissa Cláudia ^a   Keiserman, Mauro Waldemar ^a   Staub, Henrique Luiz ^a  

^a PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Antimalarials; Cholesterol; Systemic lupus erythematosus

Indexed keywords

CHLOROQUINE; CHOLESTEROL; CORTICOSTEROID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; BODY MASS; BRAZIL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; OBESITY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTIMALARIALS; CHLOROQUINE; CHOLESTEROL; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED;

EID: 79960572454     PISSN: 04825004     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Manzi S. Lupus update: perspective and clinical pearls. Cleve Clin J Med 2009; 76:137-42.
2. James JA, Kim-Howard XR, Bruner BF, Jonsson MK, Mc-Clain MT, Arbuckle MR et al. Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. Lupus 2007; 16:401-9.
3. Ardoin SP, Sandborg C, Schanberg LE. Management of dyslipidemia in children and adolescents with systemic lupus erythematosus. Lupus 2007; 16:618-26.
4. Hochberg MC. Updating the American College o Rheumatology revised criteria for the classifcation of systemic lupus erythematosus (Letter). Arthritis Rheum 1997; 40:1725.
5. World Health Organization - WHO. Physical Status: the use and interpretation of anthropometry. Technical Report Series no 854. Geneva, Switzerland: WHO, 1995.
6. NCEP - National Cholesterol Education Program. Executive summary of the third report of the national cholesterol education program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285:2486-97.
7. High blood cholesterol. National Heart, Lung, and Blood Institute. http://www.nhlbi.nih.gov/health/dci/Diseases/Hbc/HBC_all.html. Accessed April 19, 2010.
8. Oeser A, Chung CP, Asanuma Y, Avalos I, Stein CM. Obesity is an independent contributor to functional capacity and infammation in systemic lupus erythematosus. Arthritis Rheum 2005; 52:3651-59.
9. Chaiamnuay S, Bertoli AM, Fernández M, Apte M, Vilá LM, Reveille JD et al. The impact of increased body mass index on systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA XLVI). J Clin Rheumatol 2007; 13:128-33.
10. Costedoat-Chalumeau N, Leroux G, Amoura Z, Piette JC. Hydroxychloroquine and systemic lupus: a reappraisal. Rev Med Interne 2008; 29:735-7.
11. Hodis HN, Quismorio FP Jr, Wickham E, Blankenhorn DH. The lipid, lipoprotein, and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus. J Rheumatol 1993; 20:661-5.
12. Wozniacka A, Lesiak A, Smigielski J, Sysa-Jedrzejowska A. Chloroquine infuence on lipid metabolism and selected laboratory parameters. Przegl Lek 2005; 62:855-9.
13. Wallace DJ, Metzger AL, Stecher VJ, Turnbull BA, Kern PA. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med 1990; 89:322-6.
14. Tam LS, Li EK, Lam CW, Tomlinson B. Hydroxychloroquine has no signifcant effect on lipids and apolipoproteins in Chinese systemic lupus erythematosus patients with mild or inactive disease. Lupus 2000; 9:413-6.
15. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical effcacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010; 69:20-8.